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Abstract 
Background: Drug-coated balloons (DCB) are a novel therapeutic strategy for small native 
coronary artery disease. However, their safety and efficacy as compared to drug-eluting 
stents (DES) is poorly defined.  
Methods: In a multicenter, open-label, randomized non-inferiority trial, 758 patients with de-
novo lesions in coronary vessels <3mm and an indication for percutaneous coronary 
intervention were randomized 1:1 to angioplasty with DCB vs. implantation of a second-
generation DES after successful predilatation via an interactive internet-based response 
system. The primary objective of this trial was to demonstrate non-inferiority of DCB vs. DES 
regarding major adverse cardiac events (MACE, i.e., cardiac death, non-fatal myocardial 
infarction, and target-vessel revascularization) after 12 months. The non-inferiority margin 
was set at an absolute rate difference of 4%. Dual antiplatelet therapy was given according to 
current guidelines. 
Findings: There were 382 patients assigned to DCB and 376 to DES. Non-inferiority of DCB 
vs. DES was demonstrated since the 95% CI of the absolute difference in MACE in the per-
protocol set was below the predeﬁned margin (-3·83, 3·93%, p=0·0217). After 12 months, 
event proportions were similar in both groups of the full-analysis set (DCB vs. DES; MACE 
7·5 vs. 7·3%; HR 0·97 [0·58, 1·64], p=0·9180) without any statistical difference for the single 
components of the primary endpoint (DCB vs. DES; cardiac death 3·1 vs. 1·3%, HR 2·33 
[0·82, 6·61], p=0·1131; non-fatal myocardial infarction 1·6 vs. 3·5%, HR 0·46 [0·17, 1·2], 
p=0·1123; target vessel revascularization 3·4 vs. 4·5%, HR 0·75 [0·36, 1·55], p=0·4375). 
There was no statistical difference regarding stent thrombosis and major bleeding. 
Interpretation: In small native coronary artery disease, DCB was non-inferior to DES 
regarding MACE up to 12 months, with similar event rates for both treatment groups. 
Trial Registration Number: NCT01574534 (www.clinicaltrials.gov) 
Funding: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, 
Bern, Switzerland (32003B_140956); Basel Cardiovascular Research Foundation, Basel, 
Switzerland; and B. Braun Medical AG, Sempach, Switzerland.   
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Second-generation drug-eluting stents (DES) are the preferred treatment strategy for 
percutaneous coronary intervention (PCI) in coronary artery disease (CAD).1 However, the 
efficacy of stents is limited in small coronary arteries.2 This limitation applies not only to bare 
metal stents (BMS),3 but also to first- and second-generation DES.4 
Drug-coated balloons (DCB) are a novel concept for the treatment of CAD and an 
established therapeutic option for restenosis of both BMS5,6 and DES.7,8 The technique is 
based on the fast delivery of highly lipophilic drugs to the vessel wall after single balloon 
inflation using a specific matrix.9 To overcome the limitations of elastic recoil and flow-limiting 
dissections after balloon angioplasty, optimal lesion preparation is mandatory as outlined in 
current recommedations.10 The feasibility of the technique in small-vessel CAD has been 
suggested in several pilot studies.11-16 
However, a large pivotal randomized controlled trial comparing DCB with second-generation 
DES using clinical endpoints is lacking. Therefore, the objective of the Basel Kosten 
Effektivitäts Trial – Drug-Coated Balloons vs. Drug-eluting Stents in Small Vessel 
Interventions (BASKET-SMALL) 2 was to test the non-inferiority of DCB vs. second-
generation DES in small vessel CAD using a 12-month composite clinical endpoint of major 
adverse cardiac events (MACE) consisting of cardiac death, non-fatal myocardial infarction, 
and target vessel revascularization (TVR) in a large all-comer population. 
 
Methods 
Trial Design. BASKET-SMALL 2 is an investigator-initiated, prospective, randomized, 
multicenter, open-label, non-inferiority trial.17 The primary aim of this study is to demonstrate 
the non-inferiority of paclitaxel-coated balloons vs. second-generation DES regarding a 
composite of clinical endpoints in an all-comer population with native small-vessel CAD. The 
14 participating centers are listed in the supplementary Appendix, in addition to the protocol 
and the statistical analysis plan. 
Patients. All patients with an indication for PCI either due to acute coronary syndrome, 
chronic angina pectoris, or silent ischemia, and angiographic lesions in native coronary 
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arteries <3 mm in diameter were eligible for enrollment. However, randomization was only 
possible if predilatation of the lesion with an angioplasty balloon was successful, i.e., if an 
acceptable angiographic result was obtained (no higher-grade dissections NHLBI grade C-
F,18 no decreased blood flow TIMI ≤2, or no residual stenosis >30%) according to current 
consensus group recommendations.10 Exclusion criteria were concomitant PCI of large 
lesions ≥3 mm in diameter in the same epicardial coronary artery, PCI of in-stent restenosis, 
life expectancy <12 months, pregnancy, enrollment in another randomized trial, or inability to 
give informed consent. The trial was performed in accordance with the Declaration of 
Helsinki and Good Clinical Practice guidelines, and the protocol was approved by the ethics 
committees in all participating centers. All patients provided written informed consent prior to 
the intervention. In urgent cases where the intervention could not be postponed, oral consent 
was given prior to the intervention, which was documented by a second medical person not 
involved in the trial, and written informed consent was obtained after the intervention. 
Randomization and treatment. Randomization was performed 1:1 to either the paclitaxel-
coated balloon SeQuent Please® (B. Braun Melsungen AG, Germany) or one of two second-
generation DES, i.e., the everolimus-eluting Xience® stent (Abbott Vascular, Santa Clara, 
CA) or the paclitaxel-eluting Taxus Element® stent (Boston Scientific, Natick, MA), via an 
interactive internet-based response system. The study was started with Taxus Element® as 
comparator to use devices with similar agents, but later had to be continued with Xience® 
because the initial stent became unavailable.17 The sample size was consequently increased 
to conform to the different efficacy of the two DES. PCI was performed strictly according to 
current guidelines. Specifically, the DCB, which had to be 2-3 mm longer on each side than 
the predilatation balloon, was inflated at nominal pressure for a minimal time of 30 seconds.10 
In case of flow-limiting dissections or residual significant stenosis after DCB treatment, 
additional spot stenting avoiding geographic mismatch was allowed. PCI was performed 
under dual antiplatelet therapy with acetylsalicylic acid and either a thienopyridine or 
ticagrelor. After PCI, dual antiplatelet therapy was continued in stable patients for 4 weeks 
(DCB) or 6 months (DES) and in acute coronary syndrome patients for 12 months.19 In 
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patients treated with a combination of DCB and BMS, dual antiplatelet therapy was given for 
3 months, whereas it was given for 6 months in patients with DCB and DES. In patients on 
oral anticoagulation, current guidelines irrespective of DCB or DES treatment were followed.1 
Endpoints and assessments. The primary objective of this trial was to demonstrate non-
inferiority of DCB vs. DES regarding MACE after 12 months. MACE was defined as the 
composite of cardiac death, non-fatal myocardial infarction, and TVR. Cardiac death was 
defined as any death not clearly of extracardiac origin, and myocardial infarction according to 
current guidelines.20 Secondary endpoints included the single components of the primary 
endpoint, probable or definite stent thrombosis according to the ARC definition,21 major 
bleeding defined as BARC type 3 to 5 bleeding,22 and net clinical benefit defined as the 
composite of MACE and major bleeding. All endpoints were adjudicated by an independent 
Critical Events Committee. Follow-up was done using structured clinical questionnaires or 
phone calls.  
Statistical analysis. The required sample size to demonstrate non-inferiority of DCB vs. 
DES regarding MACE at 12 months was estimated to be 758 patients. This estimation was 
performed at the time when the Steering Committee decided to change comparator stents 
and based on an expected MACE rate of 7% for DCB14 and 10% for DES23 with non-
inferiority being declared if the upper limit of the two-sided 95% confidence interval (CI) of the 
absolute risk difference was <4% (non-inferiority margin). Because the event rates of 
paclitaxel-eluting stents were expected to be higher than rates of everolimus-eluting stents,24 
sample size calculation was based on the DES with expected lower event rates. Sample size 
was calculated with a resampling procedure, i.e., samples were evaluated by sampling 
various sample sizes 9999 times from binomial distributions based on expected rates, and 
was set to ensure at least 90% power (1-β=0.9) at a significance level of α=5%. Considering 
an overall dropout rate of 5%, 758 patients were necessary to ensure 720 analyzable 
patients. After the enrollment of 75% of patients, a blinded sample size re-assessment was 
performed, which suggested that the trial could be continued without increase of sample 
size.25 To test for non-inferiority, the analysis of the absolute MACE risk difference at 12 
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months between DCB and DES groups and the 2-sided 95% CI was performed on the per-
protocol set (PPS) by applying a continuity corrected modification of Wilson’s score method; 
a p-value for non-inferiority was calculated following the ZCU method.26 The analysis was 
repeated on the full-analysis set (FAS) for sensitivity. The FAS was defined as all patients 
matching inclusion criteria that provided informed consent and were assigned to a treatment 
arm. To form the PPS, patients from the FAS with major protocol violations (received neither 
DCB nor DES despite being randomized, unapproved procedures, received the opposite 
treatment than randomized due to complications) or patients lost to follow-up were excluded; 
patients in the PPS were analyzed as treated. Time-dependent occurrence of events was 
investigated with Cox proportional hazards models and Kaplan-Meier curves; hazard ratios 
(HR) are presented with 95% CI. For baseline characteristics, continuous variables are 
reported as mean and standard deviation, while categorical variables are reported as 
frequency and percent. CI presented for secondary endpoints are not adjusted for multiple 
testing and inferences drawn from these may be not reproducible. The primary analysis in 
the PPS had no missing values per-definition; in the sensitivity analyses using the FAS we 
assumed no event for patients lost to follow-up. All secondary analyses are performed on the 
FAS following the intention-to-treat principle with patients analyzed as randomized. All 
analyses were performed with the statistical software system R version 3.5.0.27 
Role of the funding source. The study sponsors did not have any role in study design, 
collection, analysis, and interpretation of data or writing of the report, and did not participate 
in the decision to submit the manuscript for publication. The Principle Investigator (RJ) and 
NG had full access to all data. The corresponding author had final responsibility for the 
decision to submit for publication. 
 
Results 
Patients. Between 2012 and 2017, 883 patients were enrolled into the trial, of which 758 
(86%) were randomized and 125 (14%) entered a separate registry. Randomization ended 
once the calculated sample size was reached. Of the randomized patients, 382 were 
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assigned to the DCB group and 376 to the DES group. Overall, 728 patients (96%) had full 
data for the primary endpoint (Fig. 1). The baseline demographic and clinical characteristics 
of the patients are shown in Table 1, while angiographic data are shown in Table 2. The two 
treatment groups were well balanced. However, the percentage of men in the DCB group 
was slightly higher than in the DES group (77 vs. 70%, p=0·0232). 
Primary endpoint. The absolute risk difference of MACE between the two treatment groups 
was 0·0005 (95% CI -0·038 to 0·039) in the PPS (Fig. 2). Since the margin of the 95% CI did 
not cross the pre-defined value of 4% (p=0·0217), non-inferiority of DCB vs. DES could be 
demonstrated. A sensitivity analysis in the FAS gave similar results, with risk difference 
assessed at -0·0012 (95% CI -0·040 to 0·037). In the FAS, proportion of MACE events after 
12 months was 7·3% in DCB and 7·5% in DES patients (HR 0·97, 95% CI 0·58 to 1·64; 
p=0·9180; Fig. 3). 
Secondary endpoints. Rates of cardiac death (3·1 vs. 1·3%; HR 2·33, 95% CI 0·82 to 6·61; 
p=0·1131), non-fatal myocardial infarction (1·6 vs. 3·5%; HR 0·46, 95% CI 0·17 to 1·20; 
p=0·1123), and TVR (3·4 vs. 4·5%; HR 0·75, 95% CI 0·36 to 1·55; p=0·4375) did not differ 
between DCB and DES patients (Fig. 6-8 in the supplementary Appendix). Probable or 
definite stent thrombosis occurred in both treatment groups since stents were implanted in 
DCB patients as well, mostly in other territories of the coronary vasculature; however, rates 
were low and not statistically different between DCB and DES patients (0·79 vs. 1·60%; HR 
0·73, 95% CI 0·16 to 3·26). Of note, there was no incidence of acute vessel closure in the 
DCB group. Rates of major bleeding were low and similar in DCB and DES patients (1·1 vs. 
2·4%; HR 0·45, 95% CI 0·14 to 1·46). Rates of the net clinical benefit were similar in DCB 
vs. DES groups (7·9 vs. 9·6%; HR 0·81, 95% CI 0·50 to 1·32). 
Prespecified subgroups. The effect of DCB vs. DES was assessed in specific pre-defined 
subgroups. None of the subgroups revealed support for strong differential effects between 
the treatment groups (Fig. 4; interaction tests).  
Exploratory analyses. Regarding the slight imbalance of sexes between the treatment 
groups, MACE proportions after 12 months were generally higher in men than in women but 
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similar within both treatment groups (males, DCB vs. DES, 7·8 vs. 8·0%; HR 0·93, 95% CI 
0·52 to 1·69; females, DCB vs. DES, 5·8 vs. 6·1%; HR 1·21, 95% CI 0·37 to 4·01). The 
interaction between sex and treatment was statistically not significant (interaction term 0·93; 
95% CI 0·25 to 3·41; p=0·9127). 
Within the two treatment groups, specific post-hoc analyses regarding the combination of 
DCB with stents (DCB group) and the different stent types (DES group) were performed (Fig. 
5). In the DCB group, 20 (5%) patients were treated with a combination of DCB and stents in 
the index lesion (mostly DES). MACE rates for DCB and stents were numerically higher than 
for DCB only (DCB/stent vs. DCB only, 15·0 vs. 6·8%; HR 2·08, 95% CI 0·61 to 7·07; 
p=0·2404). In the DES group, 94 (25%) patients were treated with paclitaxel-eluting stents, 
which had numerically higher event rates than everolimus-eluting stents (12·8 vs. 5·7%, HR 
2·04, 95% CI 0·88 to 4·76; p=0·0987). The specific HR for the comparison between DCB 
and everolimus-eluting stents was 1·21 (95% CI 0·63 to 2·32; p=0·5751) and for the 
comparison between DCB and paclitaxel-eluting stents 0·52 (95% CI 0·26 to 1·04; 
p=0·0649), respectively. 
 
Discussion 
Our trial demonstrates the non-inferiority of DCB vs. DES regarding clinical events in a large 
all-comer population undergoing PCI in native small-vessel CAD. After 12 months, MACE 
rates were low and similar for both treatment groups.  
The DCB technique is based on the interaction of a highly lipophilic drug with a coating 
matrix and allows a fast and homogenous drug delivery into the vessel wall. While many 
devices exist on the market, balloons coated with paclitaxel and iopromide have shown 
favorable clinical results and currently are most widely used.9 DCB are an established 
treatment option for the treatment of in-stent restenosis,5-8 but in native small-vessel CAD the 
technique has been tested in smaller studies only.15,16 Advantages of DCB are the potential 
for favorable vascular remodeling after angioplasty in the absence of a stent, the theoretical 
lack of any stent thrombosis, and the option of shortening dual antiplatelet therapy to only 4 
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weeks. Possible limitations go back to the early days of interventional cardiology where the 
method of plain balloon angioplasty – at that time in the absence of dual antiplatelet therapy 
– was limited by acute vessel closure due to elastic recoil and flow-limiting dissections.28 
Therefore, in our study rigorous lesion preparation according to established consensus group 
recommendations to achieve an acceptable angiographic result before DCB use was 
mandatory to avoid complications.10 
So far, only two randomized controlled trials have been performed to assess the efficacy and 
safety of DCB vs. DES in native small-vessel CAD.15,16 The PICCOLETO study tested the 
effect of a paclitaxel-eluting balloon (Dior®, Eurocor, Bonn, Germany), in which the drug 
adhered to the roughened surface without matrix, to a first-generation paclitaxel-eluting stent 
(Taxus Liberté®, Boston Scientific, Natick, MA) and was prematurely halted after 57 
patients.15 The study found an increased rate of the primary angiographic endpoint (% 
diameter stenosis) in DCB vs. DES patients after 6 months and also an increased rate of the 
combined clinical endpoint, which was mainly attributed to the lacking efficacy of the type of 
DCB and the fact that geographic mismatch was not prevented.29 In contrast, the BELLO 
study tested the efficacy of a paclitaxel-eluting balloon using urea as matrix (IN.PACT 
Falcon®, Medtronic, Santa Rosa, CA) to a first-generation paclitaxel-eluting stent (Taxus 
Liberté®) and enrolled 182 patients.16 In this study, the primary angiographic endpoint of non-
inferiority regarding angiographic in-stent/-balloon late loss after 6 months was met, while the 
combined clinical endpoint showed similar event rates for both groups after 6 and 36 
months.30 While in BELLO more than 95% of lesions were treated with optimal lesion 
preparation, this was true for only 25% in PICCOLETO. Therefore, besides the use of a DCB 
with favorable clinical data, the prevention of geographic mismatch and an optimal lesion 
preparation might have been essential for the positive result of BASKET-SMALL 2. 
Regarding the statistically not significant differences between the two treatment arms seen in 
the single components of the primary endpoint, no conclusions can be drawn as the study 
was not powered to detect differences in them and none received strong statistical support of 
an effect. The potential long-term benefit of DCB over permanently implanted stents may not 
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be seen until after a few years.30 Long-term follow-up data of the current study are still being 
collected and will be reported in due time. 
Two distinct interventional treatment entities in our trial are of special interest. First, the 
MACE rate in patients receiving bailout stents after DCB treatment was numerically higher 
than in patients treated with DCB only. A higher event rate with the combination of DCB and 
stents might be explained by accidental angiographic mismatch and is in accordance with 
previous data where increased rates of restenosis were reported when DCB were combined 
with BMS.14,15 Therefore, current guidelines on DCB therapy advocate the use of DES in 
case of unplanned stent implantation,10 and current generation “limus”-DES should be 
preferred.31 However, the combination of DCB with stents in the same lesion should be 
avoided whenever possible. Second, the MACE rates of DES patients receiving paclitaxel-
eluting stents were numerically higher than of patients receiving everolimus-eluting stents. 
This is in accordance with prior non-randomized data.23,24 However, a randomized controlled 
pilot study in small-vessel CAD found even a numerically lower event rate for paclitaxel-
eluting vs. zotarolimus-eluting stents.32 Based on the present data paclitaxel seems to be 
more efficient in the setting of the DCB than the DES technique. 
Rates of major bleeding were numerically lower in DCB than DES patients since DCB require 
a shorter dual antiplatelet therapy than DES in stable patients, i.e., 4 weeks only instead of 6 
months.10,19 The shorter duration of dual antiplatelet therapy might be of additional benefit, 
which was not accounted for in the current non-inferiority trial. 
Our study has some limitations. Specifically, the trial was initially designed with a second-
generation paclitaxel-eluting stent as comparator to the paclitaxel-eluting balloon, in order to 
use the same drug and make comparisons possible. However, since the stent became 
unavailable during the study, the comparator was changed to an everolimus-eluting stent 
with an increase of sample size. Therefore, the trial was switched from a pure comparison of 
two different devices to a more comprehensive comparison of two interventional strategies. 
In addition, there was a certain imbalance regarding sex distribution among the randomized 
groups, with more male patients being randomized to the DCB group. However, a specific 
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analysis revealed that male patients had higher event rates than women underlining the 
efficacy of DCB, and that there was no significant interaction between sex and treatment. In 
addition, extrapolation of the study’s results to other types of DCB may not be justified. 
Finally, there was no routine angiographic follow-up in the study; therefore, event rates could 
have been underestimated. Since this was a clinical trial, there was no routine core-lab 
analysis of the angiographies at trial entry and at follow-up. 
In conclusion, this is the first large randomized controlled trial testing the efficacy of a 
paclitaxel-iopromide-coated DCB vs. second-generation DES in a large all-comer population 
regarding clinical endpoints. Our study showed that DCB are non-inferior to DES in lesions of 
small native coronary arteries regarding MACE up to 12 months, with similar event rates for 
both treatment groups. Therefore, small native CAD may safely be treated with DCB after 
successful predilatation. 
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Figure legends 
Fig. 1. Patient flow-chart according to CONSORT. 
Fig. 2. Event numbers and MACE rates in the PPS and the FAS. The absolute difference in 
event rates between the DCB and the DES group is presented with the 95% conﬁdence 
intervals. The p-value tests whether the absolute difference in rates is equal to the pre-
deﬁned non-inferiority margin, 0.04. PPS, per protocol set; FAS, full analysis set; MACE, 
major adverse cardiac events; DCB, drug-coated balloons; DES, drug-eluting stents. 
Fig. 3. Cumulative incidence rates for MACE according to randomization: DCB (red), DES, 
(blue). MACE, major adverse cardiac events; DCB, drug-coated balloons; DES, drug-eluting 
stents. 
Fig. 4. MACE rates and hazard ratios (95% confidence interval) of DCB over DES for all 
subgroup analyses. Cox proportional hazards models were fitted with time-to-MACE as 
outcome and with patients censored at last observation if experiencing no event. A p-value 
for the test of the study arm and subgroup is provided. All analyses were performed on the 
full analysis set with treatment arm as assigned to patients in randomization. MACE, major 
adverse cardiac events; DCB, drug-coated balloons; DES, drug-eluting stents. 
Fig. 5. Cumulative incidence rates for MACE according to the actual treatment patients 
received: DCB (red), DCB and stent (orange), paclitaxel-eluting stent (light blue), everolimus-
eluting stent (grey). MACE, major adverse cardiac events; DCB, drug-coated balloons. 
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Table 1: Baseline Characteristics 
 DCB DES 
n 382 376 
Age (mean, SD) 67·2 (10·3) 68·4 (10·3) 
Sex Male (%) 295 (77·2) 262 (69·7) 
BMI (mean, SD) 28·4 (4·5) 28·2 (4·6) 
Smoking (%)     
Current smoker 82 (21·9) 72 (19·6) 
Former smoker 144 (38·5) 123 (33·5) 
No smoker 148 (39·6) 172 (46·9) 
Hypercholesterolemia (%) 262 (68·8) 259 (70·0) 
Arterial hypertension (%) 324 (84·8) 332 (88·8) 
Family history of CAD (%) 150 (42·6) 128 (38·0) 
Diabetes mellitus (%)     
IDDM 48 (12·6) 47 (12·6) 
NIDDM 74 (19·4) 83 (22·3) 
No diabetes 259 (68·0) 243 (65·1) 
Previous MI (%) 160 (41·9) 133 (35·4) 
Previous PCI (%) 235 (61·5) 241 (64·1) 
Previous CABG (%) 37 (9·7) 34 (9·0) 
Cerebrovascular insult (%)     
No 352 (92·4) 339 (90·2) 
Stroke 16 (4·2) 23 (6·1) 
TIA 13 (3·4) 14 (3·7) 
PAOD (%) 27 (7·1) 26 (6·9) 
COPD (%) 28 (7·3) 36 (9·6) 
Renal failure (%) 54 (14·1) 59 (15·7) 
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 DCB DES 
Presentation (%)     
STEMI 11 (2·9) 4 (1·1) 
NSTEMI 53 (13·9) 56 (14·9) 
Unstable angina 48 (12·6) 42 (11·2) 
Stable angina 270 (70·7) 274 (72·9) 
Oral anticoagulation (%) 33 (9·0) 31 (8·4) 
LVEF (%, median, IQR) 60 [50,60] 60 [55, 65] 
Continuous variables are reported as mean and standard deviation, while categorical 
variables are reported as frequency and %.  
DCB, drug coated balloon; DES, drug eluting stent; SD, standard deviation; BMI, body mass 
index, CAD coronary artery disease; IDDM, insulin dependent diabetes mellitus; NIDDM, non 
insulin dependent diabetes mellitus; MI, myocardial infarction; PCI, percutaneous coronary 
intervention; CABG, coronary artery bypass graft; TIA, transient ischemic attack; PAOD, 
peripheral arterial occlusive disease; COPD, chronic obstructive pulmonary disease; ACS, 
acute coronary syndrome; LVEF, left ventricular ejection fraction; IQR, interquartile range. 
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Table 2: Angiographic data 
 DCB DES 
Target vessel     
Left anterior descending artery (%) 128 (33·5) 116 (30·9) 
Left circumflex artery (%) 179 (46·9) 183 (48·7) 
Right coronary artery (%) 75 (19·6) 77 (20·5) 
Multi-vessel disease (%) 313 (81·9) 285 (75·8) 
Bifurcation lesion (%) 22 (5·8) 29 (8·0) 
Procedural success (%, mean, SD) 96 (19) 98 (13) 
Number of DCB or DES (mean, SD) 1·68 (0·82) 1·26 (0·55) 
Length of DCB or DES (mm; mean, SD) 23·93 (11·74) 23·18 (12·85) 
Effective size of DCB or DES (mm; mean, SD) 2.75 (2.14) 2.57 (0.25) 
Inflation pressure (atm; mean, SD) 11·06 (3·54) 13·58 (3·90) 
Duration of inflation (sec; mean, SD) 48.45 (28.24) 23.36 (18.92) 
Compliant balloon for predilatation (%) 282 (73·4) 276 (73·8) 
Continuous variables are reported as mean and standard deviation, while categorical 
variables are reported as frequency and %.  
DCB, drug coated balloon; DES, drug eluting stent; SD, standard deviation 
 
